Innovative Breakthroughs at AD/PD Conference
WATERTOWN, Mass. — Vigil Neuroscience, Inc. (NASDAQ: VIGL), a clinical-stage biotechnology company, presented groundbreaking research on its small molecule TREM2 agonist, VG-3927, during two notable oral presentations at the prestigious AD/PD™ 2025 International Conference focused on Alzheimer’s and Parkinson’s Diseases.
“We are excited to demonstrate our preclinical advancements and Phase 1 data regarding VG-3927 at this international conference,” stated Ivana Magov?evi?-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “The showcased findings emphasize VG-3927's potential as a powerful oral treatment option for Alzheimer’s disease (AD), a representation of our commitment to advancing innovative therapies.”
The Unique Profile of VG-3927
VG-3927 stands out as an oral small molecule TREM2 agonist with a remarkable pharmacological profile. It is designed to selectively target and activate membrane-bound TREM2 without binding to soluble forms, maximizing therapeutic efficacy where it’s most needed in the brain.
Highlighted by Christian Mirescu, Ph.D., Senior Vice President of Neuroimmunology, during his presentation on "Small Molecule TREM2 Agonists as Next-Generation Therapeutics for Alzheimer’s Disease," the implications of VG-3927's functioning were immense. “Engaging TREM2 provides an opportunity to mobilize the brain's immune response against multiple disease factors responsible for Alzheimer's,” remarked Mirescu.
Key Findings from Preclinical Studies
Emerging data involving 5xFAD mouse models demonstrated VG-3927's role in enhancing microglial uptake of key pathological proteins such as amyloid-beta (A?) and Tau. These findings reveal the potential for VG-3927 to address multiple components of AD pathology, thus expanding its therapeutic applicability.
Vigil’s dedication to unveiling VG-3927's potential was clearly evident during the first oral presentation on April 2, showcasing significant advancements in the treatment of Alzheimer’s by targeting TREM2.
Understanding Phase 1 Clinical Trial Results
The second presentation led by Petra Kaufmann, M.D., F.A.A.N., Chief Medical Officer, revolved around the Phase 1 study results of VG-3927. This trial involved 115 participants, including young adults, elderly individuals, and patients with Alzheimer’s. Impressively, the safety and tolerability profile of VG-3927 was remarkable, exhibiting no serious adverse events and primarily mild or moderate treatment-related adverse events.
Kaufmann noted that the data collected indicated a dependable pharmacokinetic (PK) profile, which supports the proposed once-daily administration of the medication. “At the 25 mg dose, there was a significant reduction in soluble TREM2 (sTREM2) levels in the cerebrospinal fluid (CSF), demonstrating VG-3927's effectiveness in positively influencing neuroinflammatory pathways,” she explained.
Opportunities and Clinical Advancements
With an estimated cerebral spinal fluid to unbound plasma ratio of 0.91, the results from the multiple ascending dose trials are promising, reinforcing Vigil's strategy to further advance VG-3927 into the Phase 2 studies soon. The company is committed to changing the therapeutic landscape for Alzheimer’s patients significantly.
About Vigil Neuroscience
Vigil Neuroscience focuses on developing treatments for both rare and common neurodegenerative diseases. By honing in on the vital function of microglia, these immune cells act as the brain's defense mechanism, and their restoration has the power to transform treatment modalities.
Beyond VG-3927, Vigil is also leading efforts with another clinical candidate, Iluzanebart, aimed at treating a rare neurodegenerative condition known as adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). With a clear vision and innovative strategy, Vigil Neuroscience is determined to improve the lives of patients and their families.
Frequently Asked Questions
What is VG-3927?
VG-3927 is an innovative oral small molecule TREM2 agonist being developed by Vigil Neuroscience to treat Alzheimer's disease and other neurodegenerative conditions.
What were the key findings from the latest presentations?
The presentations highlighted VG-3927's safety, tolerability, and ability to enhance neuroprotective responses through microglial activation, with significant results from Phase 1 trials.
How does VG-3927 differ from other treatments?
VG-3927 uniquely targets membrane-bound TREM2, maximizing efficacy without binding to soluble TREM2, which potentially leads to better therapeutic outcomes.
What are the next steps for VG-3927?
Vigil Neuroscience aims to advance VG-3927 into Phase 2 clinical trials, with an initial focus on establishing its efficacy in Alzheimer’s patients.
Who can be contacted for more information?
For inquiries, Leah Gibson, Vice President of Investor Relations at Vigil Neuroscience, is available via email at lgibson@vigilneuro.com.
